Please ensure Javascript is enabled for purposes of website accessibility

Why Celldex Therapeutics, Inc. Jumped Higher Today

By Brian Orelli, PhD – Nov 8, 2016 at 12:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are warming up to Celldex's newest acquisition.

Image source: Getty Images.

What happened

Celldex Therapeutics (CLDX -6.12%) is up 18.8% at 12:21 p.m. EST on Tuesday after releasing earnings yesterday after the market closed.

So what

Earnings don't typically move development-stage biotechs by double-digit percentages. After all, Celldex Therapeutics had only $2.2 million in revenue during the quarter, which was primarily from a clinical trial collaboration with Bristol-Myers Squibb and a research and development agreement with Rockefeller University -- nothing to get too excited about.

Nor was there anything too exciting about Celldex Therapeutics' earnings conference call -- because there wasn't one.

Perhaps investors are warming up to Celldex's announcement last week that it's buying privately held Kolltan Pharmaceuticals. The transaction gives Celldex two additional shots on goal, as well as a discovery program to develop additional drugs. Of course Kolltan's two clinical-stage programs are in phase 1, so Celldex's current drugs, glembatumumab vedotin and varlilumab, which have both started phase 2 development, are more important than the new molecules.

Or maybe it's the decent cash position that Celldex is in, with $203.2 million in the bank after using $24 million for operating activities during the third quarter. The acquisition of Kolltan is an all-stock deal, so it won't hurt Celldex's nest egg.

Now what

Celldex is on the hook for $172.5 million in potential development, regulatory, and commercial milestone payments to Kolltan. But those would only be owed if the drugs work, which would presumably make Celldex worth more, lowering the dilution to shareholders caused by a future secondary offering to raise additional capital to cover the milestone payments.

That's the ironic part of biotech valuation. Strong development-stage companies are able to get stronger because they can raise capital more cheaply, while struggling drugmakers, even if they eventually make it to market, often dilute their shareholders' value so much that investors own a much-smaller portion of a slightly larger pie, limiting share-price appreciation.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celldex Therapeutics. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.